Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Conditions:   Accelerated/Blast-phase Myeloproliferative Neoplasm;   Chronic-phase Myelofibrosis;   IDH2 Mutation Interventions:   Drug: Ruxolitinib;   Drug: Enasidenib Sponsors:   Michal Bar-Natan;   Celgene Corporation;   Incyte Corporation;   Myeloproliferative Neoplasms Research Consortium;   National Institutes of Health (NIH);   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials